Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03012763
Recruitment Status : Completed
First Posted : January 6, 2017
Last Update Posted : January 6, 2017
Sponsor:
Information provided by (Responsible Party):
University Medicine Greifswald

Brief Summary:
The purpose of this study is to determine pharmacokinetics of the probe-drugs sulfasalazine, given in 240 ml non-caloric water and paracetamol, fexofenadine and valsartan after oral administration, given in 240 ml non-caloric water, in 240 ml caloric drink or in 240 ml grapefruit juice prior to ingestion and to visualize the localization and to measure the filling volume of stomach, small intestine as well as ascending, transverse and descending colon by T2-weighted magnetic resonance imaging after oral administration of 240 ml water (non-caloric water), after administration of 240 ml caloric drink and after administration of 240 ml grapefruit juice.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Magnetic Resonance Imaging Administration, Oral Drug: Paracetamol Drug: Sulfasalazine Drug: Fexofenadine Drug: Valsartan Device: non-caloric water Device: caloric drink Device: grapefruit juice Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan After Oral Administration Using 240 ml Non-caloric Water, a Carbohydrate Enriched Drink and Grapefruit Juice in Correlation to the Intestinal Availability of Water as Quantified by MRI-based Volumetry in 9 Healthy Male and Female Subjects
Study Start Date : April 2016
Actual Primary Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drinking Water

Arm Intervention/treatment
Placebo Comparator: non-caloric water
50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml non-caloric water 3 h thereafter
Drug: Paracetamol
Oral administration of 250 mg paracetamol

Drug: Sulfasalazine
Oral administration of 50 mg sulfasalazine

Drug: Fexofenadine
Oral administration of 120 mg fexofenadine

Drug: Valsartan
Oral administration of 40 mg valsartan

Device: non-caloric water
Oral administration of 240 ml non-caloric water

Active Comparator: caloric drink
50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml caloric drink 3 h thereafter
Drug: Paracetamol
Oral administration of 250 mg paracetamol

Drug: Sulfasalazine
Oral administration of 50 mg sulfasalazine

Drug: Fexofenadine
Oral administration of 120 mg fexofenadine

Drug: Valsartan
Oral administration of 40 mg valsartan

Device: caloric drink
Oral administration of 240 ml caloric drink

Active Comparator: grapefruit juice
50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml grapefruit juice 3 h thereafter
Drug: Paracetamol
Oral administration of 250 mg paracetamol

Drug: Sulfasalazine
Oral administration of 50 mg sulfasalazine

Drug: Fexofenadine
Oral administration of 120 mg fexofenadine

Drug: Valsartan
Oral administration of 40 mg valsartan

Device: grapefruit juice
Oral administration of 240 ml grapefruit juice




Primary Outcome Measures :
  1. area under the concentration time curve (AUC) [ Time Frame: up to 51 h after drug administration ]
    Computed with the measured concentration of Paracetamol, Fexofenadine and Valsartan in blood samples.

  2. area under the curve of small bowel water volume [ Time Frame: up to 6.75 h after drug administration ]
    Dynamic enhanced magnetic resonance examination gradient-echo T2-weighted HASTE images (TR 1300 ms, TR 321 ms, flip-angle 160°) will be acquired on a 1.5 Tesla MRI. A tube filled with 20 ml water will be fitted on the abdomen of the volunteers in order to have an internal reference for imaging. The obtained MRI files will be investigated with common radiological software (OsiriX, Voxar 3D, Fiji, 3D slicer). From the DICOM files there will obtained: Gastrointestinal volumes and their kinetics for stomach, small bowel, colon segments and gallbladder.

  3. gastric emptying rate [ Time Frame: up to 6.75 h after drug administration ]
    Dynamic enhanced magnetic resonance examination gradient-echo T2-weighted HASTE images (TR 1300 ms, TR 321 ms, flip-angle 160°) will be acquired on a 1.5 Tesla MRI. A tube filled with 20 ml water will be fitted on the abdomen of the volunteers in order to have an internal reference for imaging. The obtained MRI files will be investigated with common radiological software (OsiriX, Voxar 3D, Fiji, 3D slicer). From the DICOM files there will obtained: Gastrointestinal volumes and their kinetics for stomach, small bowel, colon segments and gallbladder. Gastric emptying rate will be estimated as the half life of water volumen in the stomach.

  4. lag-Time of sulfapyridine (orocecal transit times) [ Time Frame: up to 51 h after drug administration ]
    Estimated as the first significant concentration (>50 or 100 ng/ml) of sulfapyridine in blood samples after administration of Sulfasalazine.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • ethnic origin: Caucasian
  • body mass index: ≥ 18.5 kg/m² and ≤ 30 kg/m²
  • good health as evidenced by the results of the clinical examination, ECG, and the laboratory check-up, which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state
  • written informed consent

Exclusion Criteria:

  • weight less than 45 kg
  • claustrophobia
  • tinnitus
  • cardiac pacemakers, metallic, plastic or silicone implants, dental retainer or metal-containing tattoos and piercings, Permanent Make-Ups, intrauterine devices
  • known allergic reactions/ hypersensitivity to the active ingredients used or to constituents of the study medication (e.g. lactose, lecithin, sulfonamides, salicylates)
  • bronchial asthma (all stages) and other known allergic diseases
  • existing cardiac, haematopoietic or hematological diseases and/or pathological findings, which might interfere with the drug's safety, tolerability and/or pharmacokinetics or the requirements for the magnetic resonance tomography
  • known hyperkalemia, hyponatremia or hypovolemia or medications that may cause these conditions.
  • Hepatic, renal or metabolic diseases and/or pathological findings, which might interfere with pharmacokinetics and pharmacodynamics of the study medication (e.g. liver failure, kidney failure, acute intermittent porphyria).
  • gastrointestinal diseases and/or pathological findings, which might interfere with gastrointestinal motility and emptying processes and interfering with pharmacokinetics and pharmacodynamics of the study medication (e.g. ileus)
  • Erythema exsudativum multiforme.
  • Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency).
  • Acute, chronic or recurrent infections.
  • drug or alcohol dependence
  • positive drug or alcohol screening
  • smokers of 10 or more cigarettes per day
  • positive results in HIV, hepatitis B virus and hepatitis C virus screenings
  • subjects who are on a diet which could affect gastrointestinal motility or the pharmacokinetics of the drug (vegetarian, vegan)
  • eating disorders e.g. anorexia, bulimia
  • heavy tea or coffee drinkers (more than 1l per day)
  • lactation and/or pregnancy test positive or not performed
  • subjects suspected or known not to follow instructions
  • subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
  • subjects liable to orthostatic dysregulation, fainting or blackouts
  • participation in a clinical trial during the last 3 months prior to the planned start of the study less than 3 months after last blood donation
  • therapy with transdermal patches
  • any systemically available medication within 2 weeks prior to the intended first administration unless because of the terminal elimination half-life complete elimination from the body can be assumed for the drug and/or its primary metabolites (except oral contraceptives)
  • intake of grapefruit or poppy seeds containing products within 14 days prior to the start of the study
  • Females who don't fulfil the criteria for contraception as listed in section 7.5.1 of this protocol

Layout table for additonal information
Responsible Party: University Medicine Greifswald
ClinicalTrials.gov Identifier: NCT03012763    
Other Study ID Numbers: GIT-Physiol_2016
First Posted: January 6, 2017    Key Record Dates
Last Update Posted: January 6, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acetaminophen
Fexofenadine
Sulfasalazine
Valsartan
Terfenadine
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Anti-Infective Agents
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents